Literature DB >> 34429586

The Clinical Efficacy of Three Different Follicle-Stimulating Hormones for Follicle Growth and Development in Long-Protocol Controlled Ovarian Hyperstimulation Treatment.

Xi-Qian Zhang1, Li-Jia Zhang1, Xiu-Lan Zhu1, Hong Xu1, Yan-Qun Luo1, Li Yao1, Qian-Wen Huang1, Ying-Qi Nong1, Wen-Juan Liu1, Feng-Hua Liu1.   

Abstract

OBJECTIVE: To compare the use and clinical efficacy of three different follicle-stimulating hormones (FSHs) for follicle growth and development in long-protocol controlled ovarian hyperstimulation (COH).
METHODS: A total of 540 gonadotropin-releasing hormone (GnRH) agonists' long protocol treatment cycles at our hospital between January 2015 and May 2020 and met the inclusion criteria were retrospectively analyzed. The cycles were divided into three groups based on their indexes (groups A, B, and C). Each of the groups received a different type of FSH during treatment. A cross-group comparison was then undertaken to evaluate the growth and development of the three largest follicles and the patients' pregnancy-related indexes between the normal-response and high-response populations.
RESULTS: In the normal-response populations, the number of high-quality embryos obtained in groups A and B was significantly higher than in group C, and the FSH dosage was significantly lower than in group C (P < 0.05). There were more follicles with a diameter of 16-18 mm found in group A than in group C on the day of hCG injection (hCG day) (P < 0.05), but there were no significant differences in the groups in other indicators. In the high-response populations, the number of oocytes retrieved and high-quality embryos obtained in group A were significantly higher than in group C (P < 0.05), and the total dosage and duration of FSH stimulation in group C were significantly higher than groups A and B (P < 0.05).
CONCLUSION: Three different types of FSH led to comparable growth rates of the three largest follicles and clinical pregnancy rates per fresh cycle in long-protocol COH treatment.
© 2021 Zhang et al.

Entities:  

Keywords:  Gn stimulation duration; follicle distribution on hCG day; follicle growth rate; follicle-stimulating hormone; high-quality embryos

Mesh:

Substances:

Year:  2021        PMID: 34429586      PMCID: PMC8378929          DOI: 10.2147/DDDT.S316189

Source DB:  PubMed          Journal:  Drug Des Devel Ther        ISSN: 1177-8881            Impact factor:   4.162


  13 in total

1.  Association of semenogelin (SEMG) gene variants in idiopathic male infertility in Chinese-Han population.

Authors:  Jing Wu; Xingxuan Dong; Kaifan Liu; Yankai Xia; Xinru Wang; Ouxi Shen; Xinliang Ding; Jie Zhang
Journal:  J Toxicol Environ Health A       Date:  2019-09-19

2.  Should we consider integrated approach for endometriosis-associated infertility as gold standard management? Rationale and results from a large cohort analysis.

Authors:  Vesna Šalamun; Ivan Verdenik; Antonio Simone Laganà; Eda Vrtačnik-Bokal
Journal:  Arch Gynecol Obstet       Date:  2017-12-22       Impact factor: 2.344

3.  Successful treatment of infertile women with hypothalamic primary and secondary protracted amenorrhoea using gonadotrophin releasing hormone analogue and human menopausal gonadotrophin.

Authors:  M A Aboulghar; R T Mansour; G I Serour; A M Ramzy
Journal:  Hum Reprod       Date:  1990-07       Impact factor: 6.918

4.  Comparison of the efficacy and safety of a new recombinant human follicle-stimulating hormone (DA-3801) with follitropin-alpha (Gonal-F) in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology.

Authors:  Shin Yong Moon; Young Sik Choi; Seung-Yup Ku; Seok Hyun Kim; Young Min Choi; Inn Soo Kang; Chung Hoon Kim
Journal:  J Obstet Gynaecol Res       Date:  2007-06       Impact factor: 1.730

5.  Differences in gene expression of granulosa cells from women undergoing controlled ovarian hyperstimulation with either recombinant follicle-stimulating hormone or highly purified human menopausal gonadotropin.

Authors:  Marie Louise Grøndahl; Rehannah Borup; Young Bae Lee; Vibeke Myrhøj; Helle Meinertz; Steen Sørensen
Journal:  Fertil Steril       Date:  2008-04-25       Impact factor: 7.329

6.  Are we choosing the correct FSH starting dose during controlled ovarian stimulation for intrauterine insemination cycles? Potential application of a nomogram based on woman's age and markers of ovarian reserve.

Authors:  Rossana Di Paola; Simone Garzon; Sara Giuliani; Antonio Simone Laganà; Marco Noventa; Francesca Parissone; Carlotta Zorzi; Ricciarda Raffaelli; Fabio Ghezzi; Massimo Franchi; Stefano Zaffagnini
Journal:  Arch Gynecol Obstet       Date:  2018-09-21       Impact factor: 2.344

7.  Comparison of human menopausal gonadotropin and follicle-stimulating hormone with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation in in vitro fertilization.

Authors:  T S Yang; B C Wang; S P Chang; H T Ng
Journal:  Zhonghua Yi Xue Za Zhi (Taipei)       Date:  1995-06

Review 8.  Breakthroughs in the Use of Inositols for Assisted Reproductive Treatment (ART).

Authors:  Fabio Facchinetti; Maria Salome Bezerra Espinola; Didier Dewailly; Ali Cenk Ozay; Nikos Prapas; Mónica Vazquez-Levin; Artur Wdowiak; Vittorio Unfer
Journal:  Trends Endocrinol Metab       Date:  2020-05-15       Impact factor: 12.015

9.  Are ovarian reserve tests reliable in predicting ovarian response? Results from a prospective, cross-sectional, single-center analysis.

Authors:  Carla Peluso; Renato de Oliveira; Gabriel Zorello Laporta; Denise Maria Christofolini; Fernando Luiz Affonso Fonseca; Antonio Simone Laganà; Caio Parente Barbosa; Bianca Bianco
Journal:  Gynecol Endocrinol       Date:  2020-07-02       Impact factor: 2.260

10.  Manufacturing of Recombinant Human Follicle-Stimulating Hormone Ovaleap® (XM17), Comparability with Gonal-f®, and Performance/Consistency.

Authors:  Rainer Winstel; Juergen Wieland; Beate Gertz; Arnd Mueller; Hermann Allgaier
Journal:  Drugs R D       Date:  2017-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.